Stockscreener 앱 받기
1.90
3.26%
0.06
시간 외 거래:
1.94
0.04
+2.11%
전일 마감가:
$1.84
열려 있는:
$1.88
하루 거래량:
540.90K
Relative Volume:
0.66
시가총액:
$63.78M
수익:
-
순이익/손실:
$-51.50M
주가수익비율:
-0.475
EPS:
-4
순현금흐름:
$-47.10M
1주 성능:
-1.55%
1개월 성능:
+0.53%
6개월 성능:
+11.11%
1년 성능:
-74.39%
1일 변동 폭
$1.81
$1.91
1주일 범위
$1.785
$2.05
52주 변동 폭
$0.87
$8.32
아웃룩 테라퓨틱스 Stock (OTLK) Company Profile
명칭
Outlook Therapeutics Inc
전화
(609) 619-3990
주소
111 S. WOOD AVENUE, ISELIN, NJ
OTLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.90 | 80.57M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
아웃룩 테라퓨틱스 Stock (OTLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-27 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-13 | 개시 | CapitalOne | Overweight |
| 2023-04-03 | 개시 | Guggenheim | Buy |
| 2023-02-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 개시 | BTIG Research | Buy |
| 2022-09-13 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2019-05-16 | 개시 | Oppenheimer | Outperform |
| 2019-04-22 | 개시 | Ascendiant Capital Markets | Buy |
모두보기
아웃룩 테라퓨틱스 주식(OTLK)의 최신 뉴스
Outlook Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 15:25:16 - metal.it
What are analysts’ price targets for Outlook Therapeutics Inc. in the next 12 monthsUnlock high-yield investment opportunities - Jammu Links News
What institutional investors are buying Outlook Therapeutics Inc. stockTriple-digit profit margins - Jammu Links News
What are the latest earnings results for Outlook Therapeutics Inc.Game-changing capital returns - Jammu Links News
What is the dividend policy of Outlook Therapeutics Inc. stockFree Capital Allocation Plans - Jammu Links News
How volatile is Outlook Therapeutics Inc. stock compared to the marketExceptional portfolio growth - Jammu Links News
When is Outlook Therapeutics Inc. stock expected to show significant growthExplosive portfolio gains - Jammu Links News
Is Outlook Therapeutics Inc. a good long term investmentUnrivaled growth potential - Jammu Links News
How strong is Outlook Therapeutics Inc. company’s balance sheetCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Outlook Therapeutics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
What makes Outlook Therapeutics Inc. stock price move sharplyInvest confidently with expert support - Jammu Links News
What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Achieve breakthrough performance in the market - Jammu Links News
Should I hold or sell Outlook Therapeutics Inc. stock in 2025Capitalize on emerging market sectors - Jammu Links News
How does Outlook Therapeutics Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
What is Outlook Therapeutics Inc. company’s growth strategyPre Market Recommendation With Low Risk - Jammu Links News
Outlook Therapeutics, Inc. shares rise 1.95% premarket after Eli Lilly's Mounjaro shows heart benefits in a head-to-head study. - AInvest
What institutions are buying Outlook Therapeutics Inc. stock nowEntry Points For Growing Stocks Identified by Models - metal.it
Ichimoku Cloud Indicates Uncertainty Around Outlook Therapeutics Inc.Real Trader Watchlist of Hot Stocks Released - metal.it
What caused OTLK's net profit surge in Q3 2024? - AInvest
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
How many analysts rate Outlook Therapeutics Inc. as a “Buy”Build your wealth with consistent stock growth - Jammu Links News
Outlook Therapeutics Inc. stock outlook for YEAR Pattern Recognition Based Market Move Prediction - Newser
Why is Outlook Therapeutics Inc. stock attracting strong analyst attentionInvest confidently with professional market insights - Jammu Links News
Published on: 2025-07-28 00:00:40 - Jammu Links News
Top Risks to Consider Before Buying Outlook Therapeutics Inc. StockSafe High Return Entry Points - Newser
Outlook Therapeutics Inc. Stock Support and Resistance Levels You Should KnowBig Return Stock Tips - Newser
Why Outlook Therapeutics Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
Outlook Therapeutics, Inc. shares fall 2.45% after-hours amid mixed market sentiment. - AInvest
What analysts say about Outlook Therapeutics Inc. stockPowerful growth strategies - PrintWeekIndia
Outlook Therapeutics to Present at OIS Retina Innovation Summit - AInvest
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Outlook Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - printweek.in
Outlook Therapeutics to Present at the 8th Annual Ophthalmology - GuruFocus
Outlook Therapeutics Showcases Breakthrough Retina Treatment Innovation at Elite Ophthalmology Summit - Stock Titan
What drives Outlook Therapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
아웃룩 테라퓨틱스 (OTLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):